QQQ   354.07 (-1.54%)
AAPL   172.24 (-2.18%)
MSFT   310.52 (-2.21%)
META   298.49 (-0.78%)
GOOGL   128.24 (-2.19%)
AMZN   125.88 (-4.11%)
TSLA   244.56 (-0.98%)
NVDA   420.21 (-0.48%)
NIO   8.40 (+0.60%)
BABA   85.89 (-1.52%)
AMD   95.73 (-1.69%)
T   15.03 (-0.20%)
F   12.45 (-1.03%)
MU   67.85 (-1.06%)
CGC   0.92 (-2.85%)
GE   110.07 (-1.48%)
DIS   80.00 (-1.25%)
AMC   7.95 (-2.33%)
PFE   32.56 (-1.27%)
PYPL   58.79 (-0.12%)
NFLX   378.14 (-1.73%)
QQQ   354.07 (-1.54%)
AAPL   172.24 (-2.18%)
MSFT   310.52 (-2.21%)
META   298.49 (-0.78%)
GOOGL   128.24 (-2.19%)
AMZN   125.88 (-4.11%)
TSLA   244.56 (-0.98%)
NVDA   420.21 (-0.48%)
NIO   8.40 (+0.60%)
BABA   85.89 (-1.52%)
AMD   95.73 (-1.69%)
T   15.03 (-0.20%)
F   12.45 (-1.03%)
MU   67.85 (-1.06%)
CGC   0.92 (-2.85%)
GE   110.07 (-1.48%)
DIS   80.00 (-1.25%)
AMC   7.95 (-2.33%)
PFE   32.56 (-1.27%)
PYPL   58.79 (-0.12%)
NFLX   378.14 (-1.73%)
QQQ   354.07 (-1.54%)
AAPL   172.24 (-2.18%)
MSFT   310.52 (-2.21%)
META   298.49 (-0.78%)
GOOGL   128.24 (-2.19%)
AMZN   125.88 (-4.11%)
TSLA   244.56 (-0.98%)
NVDA   420.21 (-0.48%)
NIO   8.40 (+0.60%)
BABA   85.89 (-1.52%)
AMD   95.73 (-1.69%)
T   15.03 (-0.20%)
F   12.45 (-1.03%)
MU   67.85 (-1.06%)
CGC   0.92 (-2.85%)
GE   110.07 (-1.48%)
DIS   80.00 (-1.25%)
AMC   7.95 (-2.33%)
PFE   32.56 (-1.27%)
PYPL   58.79 (-0.12%)
NFLX   378.14 (-1.73%)
QQQ   354.07 (-1.54%)
AAPL   172.24 (-2.18%)
MSFT   310.52 (-2.21%)
META   298.49 (-0.78%)
GOOGL   128.24 (-2.19%)
AMZN   125.88 (-4.11%)
TSLA   244.56 (-0.98%)
NVDA   420.21 (-0.48%)
NIO   8.40 (+0.60%)
BABA   85.89 (-1.52%)
AMD   95.73 (-1.69%)
T   15.03 (-0.20%)
F   12.45 (-1.03%)
MU   67.85 (-1.06%)
CGC   0.92 (-2.85%)
GE   110.07 (-1.48%)
DIS   80.00 (-1.25%)
AMC   7.95 (-2.33%)
PFE   32.56 (-1.27%)
PYPL   58.79 (-0.12%)
NFLX   378.14 (-1.73%)
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Competitors

$20.20
+0.05 (+0.25%)
(As of 03:03 PM ET)
Compare
Today's Range
$20.09
$21.12
50-Day Range
$20.09
$25.82
52-Week Range
$18.84
$33.49
Volume
109,328 shs
Average Volume
285,711 shs
Market Capitalization
$606.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.75

BCYC vs. PHAT, SPRY, TYRA, CDMO, CNTA, DYN, ALPN, RAPT, ELVN, and GNLX

Should you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Phathom Pharmaceuticals (PHAT), ARS Pharmaceuticals (SPRY), Tyra Biosciences (TYRA), Avid Bioservices (CDMO), Centessa Pharmaceuticals (CNTA), Dyne Therapeutics (DYN), Alpine Immune Sciences (ALPN), RAPT Therapeutics (RAPT), Enliven Therapeutics (ELVN), and Genelux (GNLX). These companies are all part of the "pharmaceutical preparations" industry.

Bicycle Therapeutics vs.

Bicycle Therapeutics (NASDAQ:BCYC) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

In the previous week, Bicycle Therapeutics had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 6 mentions for Bicycle Therapeutics and 4 mentions for Phathom Pharmaceuticals. Bicycle Therapeutics' average media sentiment score of 0.41 beat Phathom Pharmaceuticals' score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicycle Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Phathom Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bicycle Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Phathom Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -621.69%. Phathom Pharmaceuticals' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bicycle Therapeutics-621.69% -54.71% -32.73%
Phathom Pharmaceuticals N/A N/A -95.34%

Bicycle Therapeutics presently has a consensus price target of $48.75, suggesting a potential upside of 141.34%. Phathom Pharmaceuticals has a consensus price target of $23.33, suggesting a potential upside of 124.36%. Given Bicycle Therapeutics' higher probable upside, equities research analysts clearly believe Bicycle Therapeutics is more favorable than Phathom Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Phathom Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 93.1% of Phathom Pharmaceuticals shares are held by institutional investors. 10.2% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 7.5% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bicycle Therapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicycle Therapeutics$14.46M41.96-$112.72M-$4.68-4.32
Phathom PharmaceuticalsN/AN/A-$197.72M-$4.38-2.37

Bicycle Therapeutics received 60 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. Likewise, 67.47% of users gave Bicycle Therapeutics an outperform vote while only 61.90% of users gave Phathom Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Bicycle TherapeuticsOutperform Votes
112
67.47%
Underperform Votes
54
32.53%
Phathom PharmaceuticalsOutperform Votes
52
61.90%
Underperform Votes
32
38.10%

Summary

Bicycle Therapeutics beats Phathom Pharmaceuticals on 10 of the 17 factors compared between the two stocks.


Get Bicycle Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCYC vs. The Competition

MetricBicycle TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$606.81M$5.64B$4.40B$6.20B
Dividend YieldN/A2.71%5.85%9.77%
P/E Ratio-4.324.71119.4811.88
Price / Sales41.96162.832,845.2271.79
Price / CashN/A19.6021.5122.68
Price / Book2.213.854.484.61
Net Income-$112.72M$197.90M$123.21M$185.80M
7 Day Performance-6.18%-2.82%-1.68%-2.84%
1 Month Performance-13.93%-7.74%-3.37%-4.79%
1 Year Performance-9.90%9.04%11.02%5.96%

Bicycle Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHAT
Phathom Pharmaceuticals
1.5247 of 5 stars
$11.08
-8.5%
$23.33
+110.6%
+9.3%$629.34MN/A-2.53112News Coverage
High Trading Volume
SPRY
ARS Pharmaceuticals
1.973 of 5 stars
$6.61
-11.3%
$15.33
+132.1%
N/A$631.24M$1.32M0.0029Insider Buying
Analyst Revision
News Coverage
Gap Up
High Trading Volume
TYRA
Tyra Biosciences
1.8534 of 5 stars
$14.69
+0.1%
$24.00
+63.4%
+89.1%$631.82MN/A-12.2438Positive News
CDMO
Avid Bioservices
2.2607 of 5 stars
$9.69
-2.9%
$20.00
+106.4%
-46.1%$611.54M$149.27M-242.25365Positive News
CNTA
Centessa Pharmaceuticals
2.1645 of 5 stars
$6.59
+1.5%
$8.50
+29.0%
+41.5%$641.87MN/A-3.6464Positive News
DYN
Dyne Therapeutics
2.3116 of 5 stars
$9.86
+0.1%
$27.20
+175.9%
-30.1%$601.66MN/A-2.90134
ALPN
Alpine Immune Sciences
1.5988 of 5 stars
$12.15
-3.5%
$18.00
+48.1%
+73.9%$597.78M$30.06M-8.80126Positive News
RAPT
RAPT Therapeutics
2.4437 of 5 stars
$19.09
-0.3%
$38.18
+100.0%
-24.4%$657.61M$1.53M-7.10122Positive News
ELVN
Enliven Therapeutics
2.4337 of 5 stars
$14.30
-8.6%
$27.00
+88.8%
N/A$588.45MN/A4.7837Positive News
GNLX
Genelux
1.2774 of 5 stars
$27.42
+8.0%
$25.00
-8.8%
N/A$676.45M$11.07M0.0020Insider Selling
High Trading Volume

Related Companies and Tools

This page (NASDAQ:BCYC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -